CLDX241115C60000
- 0.33
- 0.000.00%
Celldex Therapeutics Newsroom
Celldex Therapeutics Analyst Ratings
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $90
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $78
Goldman Sachs Maintains Celldex Therapeutics(CLDX.US) With Hold Rating, Maintains Target Price $45
Citi Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $70
Celldex (CLDX) Gets a Buy From Citi
Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Initiated at Neutral by Goldman Sachs
Goldman Sachs Initiates Celldex Therapeutics(CLDX.US) With Hold Rating, Announces Target Price $45
Hold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive Challenges
TD Cowen Maintains Celldex Therapeutics(CLDX.US) With Buy Rating
Leerink Partners Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $78
Wolfe Research Downgrades Celldex Therapeutics(CLDX.US) to Hold Rating, Maintains Target Price $51
TD Cowen Maintains Celldex Therapeutics(CLDX.US) With Buy Rating
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $80
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $67
Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald